Implementing Single Use Technologies in Sterile Vaccines Processing

Implementing Single Use Technologies in Sterile Vaccines Processing

This on-demand webinar presented by Charlotte Masy of GSK is a case study illustration of GSK’s strategic approach for sterility assurance.

One of the main challenges when considering single-use technologies in sterile vaccines manufacturing is to ensure the highest level of assurance of integrity and sterility.

 

This webinar presented by Charlotte Masy of GSK is a case study illustration of GSK’s strategic approach for sterility assurance.

 

 Topics covered:

 

  • How a Quality by Design (QbD) approach has been applied to develop, design and qualify single-use systems for vaccine manufacturing
  • How GSK manage sterility assurance concerns
  • Assessing and mitigating risks to integrity of SUS in sterile applications

 

Speaker

 

 

Charlotte Masy

Charlotte Masy

 

Technical Lifecycle Project Manager 

TLCM-MSAT

GlaxoSmithKline

Learn more about the Helium Integrity Test

Manage risk in your critical process with this high sensitivity, supplier integrity test for single-use systems, filling sets and mixer biocontainers

더 Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
May 2021
Overcome Exosome Production Challenges

Biotech | Pall Corporation 웨비나 시리즈

This webinar was recorded by BioPharma Asia and first published on their website. https://biopharma-asia.com. It is made available here by kind permission of BioPharma Asia and the presenters.

 

Hailed as the “next frontier” in cell therapy and regenerative medicine, exosomes are a type of extracellular vesicle and play a key role in the regulation of the intercellular communication processes.

David Haylock of VivaZome will present on upstream production of angiogenic exosomes using the iCELLis® nano fixed bed bioreactor. This will be followed by a presentation by Roberto Ciboldi of Pall Corporation on a platform solution including cell culture, purification and sterile filtration of exosomes.

Participants will be able to:

 

  • Compare the performance of the iCELLis Nano bioreactor to traditional flasks for exosome production from adherent cell culture
  • Understand how an integrated end to end platform delivers highly   purified and consistently-sized exosomes
  • Discover an innovative cGMP scalable manufacturing platform for   exosomes
시청